Amanta Healthcare Reports Q2 Profit, Completes IPO Listing
Amanta Healthcare Limited reported Q2 FY2026 results with total income of Rs. 7,095.80 lakhs and net profit of Rs. 207.80 lakhs. For H1 FY2026, total income was Rs. 13,850.45 lakhs with net profit of Rs. 185.50 lakhs. The company completed its IPO, issuing 10 million shares at Rs. 126 each, raising Rs. 12,600 lakhs. Listing occurred on September 9, 2025, on BSE and NSE. IPO proceeds are allocated for new manufacturing lines and corporate purposes, with Rs. 3,030.02 lakhs utilized so far. PriceWaterhouseCoopers provided an unmodified review opinion on the financial results.
*this image is generated using AI for illustrative purposes only.
Amanta Healthcare Limited , a pharmaceutical manufacturing and contract manufacturing services company, has reported its financial results for the quarter ended September 30, 2025, along with the successful completion of its Initial Public Offering (IPO).
Financial Performance
For the quarter ended September 30, 2025, Amanta Healthcare reported:
| Particulars | Q2 FY2026 (Rs. in lakhs) |
|---|---|
| Total Income | 7,095.80 |
| Net Profit | 207.80 |
For the half-year ended September 30, 2025, the company's performance was as follows:
| Particulars | H1 FY2026 (Rs. in lakhs) |
|---|---|
| Total Income | 13,850.45 |
| Net Profit | 185.50 |
IPO Completion and Listing
Amanta Healthcare successfully completed its Initial Public Offering during the quarter. Key details of the IPO include:
- Number of equity shares issued: 10,000,000
- Issue price: Rs. 126 per share
- Total funds raised: Rs. 12,600 lakhs
- Listing date: September 9, 2025
- Listed on: BSE Limited and National Stock Exchange of India Limited
The company recognized IPO-related expenses of Rs. 262.88 lakhs as an exceptional item in its financial statements.
Utilization of IPO Proceeds
The company has outlined the following utilization plan for the IPO proceeds:
| Purpose | Amount Allocated (Rs. in lakhs) | Amount Utilized (Rs. in lakhs) | Amount Unutilized (Rs. in lakhs) |
|---|---|---|---|
| New manufacturing line for SteriPort | 7,000.00 | 764.81 | 6,235.19 |
| New manufacturing line for SVP | 3,013.11 | - | 3,013.11 |
| General corporate purposes | 302.08 | 302.08 | - |
| Issue Expenses | 2,284.81 | 2,265.21 | 19.60 |
| Total | 12,600.00 | 3,030.02 | 9,569.98 |
Auditor's Review
PriceWaterhouseCoopers provided an unmodified review opinion on the financial results for the quarter and half-year ended September 30, 2025.
Amanta Healthcare's successful IPO and listing mark a significant milestone for the company, providing it with capital for potential expansion and growth in the pharmaceutical manufacturing sector.
Historical Stock Returns for Amanta Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +7.14% | +5.16% | -8.91% | -23.11% | -23.11% | -23.11% |
16
